MedTrace Logo

Cervical Cancer Radiotherapy by Use of VMAT, Individualized Polyradiosensitization and Interstitial Brachytherapy

NCT02957266 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2016-11-15

No results posted yet for this study

Summary

The purpose of this study is to define an effectiveness of concurrent chemoradiotherapy of cervical cancer patients treated by VMAT (volumetric arc therapy) based external beam radiotherapy, polyradiosensitization by cisplatin and gemcitabine and interstitial brachytherapy.

Conditions

Interventions

RADIATION

Volumetric Arc Radiotherapy

Volumetric Arc Radiotherapy

RADIATION

Interstitial brachytherapy

Interstitial High Dose Rate Brachytherapy

DRUG

Cisplatin

Weekly Cisplatin

DRUG

Gemcitabine

Weekly Gemcitabine

GENETIC

PIK3CA

PIK3CA mutations rate

GENETIC

KRAS

KRAS mutations rate

GENETIC

BRAF

BRAF mutations rate

GENETIC

RRM1

RRM1 mutations rate

Sponsors & Collaborators

  • The National Center of Oncology, Azerbaijan

    lead OTHER_GOV

Principal Investigators

  • Kamal Akbarov, PhD · National Center of Oncology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2018-12-31
Completion
2020-12-31

Countries

  • Azerbaijan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02957266 on ClinicalTrials.gov